Literature DB >> 12191636

Epigenetic versus genetic alterations in the inactivation of E-cadherin.

Gordon Strathdee1.   

Abstract

Genetic mutation of genes that inhibit the formation of tumours has long been known to be one of the main driving forces in the development of cancer. Inactivation of one such gene, E-cadherin, is thought to be an important step in the development of most, or all, epithelial derived tumour types. Mutations within the E-cadherin gene have been identified as the cause of familial gastric cancer and loss of expression of E-cadherin has been found to be widespread in sporadically occurring epithelial tumours. Despite this, mutations of the E-cadherin gene have been only rarely found in most types of sporadic cancers. However, recent evidence has identified a second mechanism potentially responsible for inactivation of E-cadherin, and other important genes, during tumourigenesis, namely DNA methylation. This review will examine the importance of genetic (mutation) versus epigenetic (DNA methylation) mechanisms in the inactivation of E-cadherin during tumour development and also discuss potential differences in the functional consequences between inactivation by epigenetic or genetic means.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12191636     DOI: 10.1016/s1044-579x(02)00057-3

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  51 in total

Review 1.  Involvement of members of the cadherin superfamily in cancer.

Authors:  Geert Berx; Frans van Roy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-09-23       Impact factor: 10.005

2.  Cervical cancer pathogenesis is associated with one-carbon metabolism.

Authors:  Sujata Pathak; Neerja Bhatla; Neeta Singh
Journal:  Mol Cell Biochem       Date:  2012-06-23       Impact factor: 3.396

3.  Nickel-induced epithelial-mesenchymal transition by reactive oxygen species generation and E-cadherin promoter hypermethylation.

Authors:  Chih-Hsien Wu; Sheau-Chung Tang; Po-Hui Wang; Huei Lee; Jiunn-Liang Ko
Journal:  J Biol Chem       Date:  2012-05-30       Impact factor: 5.157

Review 4.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

Review 5.  Loss of E-Cadherin-Dependent Cell-Cell Adhesion and the Development and Progression of Cancer.

Authors:  Heather C Bruner; Patrick W B Derksen
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-03-01       Impact factor: 10.005

Review 6.  The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression.

Authors:  Grégoire F Le Bras; Kenneth J Taubenslag; Claudia D Andl
Journal:  Cell Adh Migr       Date:  2012-07-01       Impact factor: 3.405

Review 7.  Epigenetic mechanisms in Alzheimer's disease.

Authors:  Diego Mastroeni; Andrew Grover; Elaine Delvaux; Charisse Whiteside; Paul D Coleman; Joseph Rogers
Journal:  Neurobiol Aging       Date:  2011-04-11       Impact factor: 4.673

Review 8.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

9.  Holding Tight: Cell Junctions and Cancer Spread.

Authors:  Alexander J Knights; Alister P W Funnell; Merlin Crossley; Richard C M Pearson
Journal:  Trends Cancer Res       Date:  2012

10.  The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.

Authors:  A B D'Assoro; T Liu; C Quatraro; A Amato; M Opyrchal; A Leontovich; Y Ikeda; S Ohmine; W Lingle; V Suman; J Ecsedy; I Iankov; A Di Leonardo; J Ayers-Inglers; A Degnim; D Billadeau; J McCubrey; J Ingle; J L Salisbury; E Galanis
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.